Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study comparing a steroid sparing versus a standard steroid regimen in combination with CellCept [mycophenolate mofetil], Zenapax [daclizumab] and sirolimus in the prevention of acute renal allograft rejection

Next Previous
X
Search
Trial Profile

An open-label study comparing a steroid sparing versus a standard steroid regimen in combination with CellCept [mycophenolate mofetil], Zenapax [daclizumab] and sirolimus in the prevention of acute renal allograft rejection

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclizumab (Primary) ; Mycophenolate mofetil; Prednisolone; Sirolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 07 Apr 2022 This trial has been completed in Spain (End Date: 11 Jul 2006), according to European Clinical Trials Database record.
    • 23 Feb 2010 Actual initiation date (Apr 2006) added as reported by Roche record.
    • 23 Mar 2008 Updated study design, study control, and descriptor, from Roche record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top